Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Phase III HIT-HGG trial in pediatric high-grade glioma
DRKS00012806Phase 3Recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Aug 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of temozolomide and valproic acid in glioblastoma (GBM), diffuse midline glioma (DMG), anaplastic astrocytoma (AA) and 2 more, sponsored by Universitätsmedizin Göttingen. Started Aug 2017; status: recruiting.
02
Drugs
temozolomidevalproic acid
03
Conditions
glioblastoma (GBM)diffuse midline glioma (DMG)anaplastic astrocytoma (AA)diffuse intrinsic pontine glioma (DIPG)gliomatosis cerebri (GC)
Beyond the preview
Go deeper on DRKS00012806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00012806.